Ionis Pharmaceuticals Inc

Quantli Newsdesk

· a month ago

Wainua, a gene-silencing drug co-developed by Ionis and AstraZeneca, missed its primary endpoint in a Phase 3 trial for ATTR-CM, a progressive heart disease affecting up to 500,000 people worldwide. The drug failed to show statistically significant cardiovascular benefit when added to standard care, though a subgroup not taking stabilizers showed nominal improvement. Ionis shares fell as much as 15% in premarket trading.